![]() By providing your cell phone number, you represent that you are the authorized user of the wireless device you use to receive the messages and that you are authorized to approve any changes. When you opt-in to the service, we will send you an SMS message to confirm your signup. These SMS messages are sent through PSKW, LLC dba ConnectiveRx, a service provider partner operating on behalf of Salix Pharmaceuticals, a subsidiary of Bausch Health Companies, Inc. To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-80 or FDA at 1-80 or Please click here for full Prescribing Information.XIFAXAN Savings Program SMS (text) messages are recurring automated copay program messages, which may include savings alerts, refill reminders, and other messages related to your participation in the copay program. Adverse reactions were similar between the two dosing regimens. In clinical trials, the most common adverse reactions (>2% of patients taking PLENVU ®) were nausea, vomiting, dehydration, and abdominal pain/discomfort.Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should signs and symptoms occur. PLENVU ® contains polyethylene glycol and may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus.Each PLENVU ® treatment contains 491 mg of phenylalanine. PLENVU ® contains phenylalanine, a component of aspartame. Phenylalanine can be harmful to patients with phenylketonuria (PKU).Use PLENVU ® with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. ![]() Do not combine PLENVU ® with starch-based thickeners. Patients with impaired gag reflex or those prone to regurgitation or aspiration should be observed during the administration of PLENVU ®.Use caution in patients with severe ulcerative colitis.If GI obstruction or perforation is suspected, perform appropriate diagnostic studies prior to administering PLENVU ®. Do not administer PLENVU ® to patients with GI obstruction or perforation.Advise these patients to adequately hydrate before, during, and after the use of PLENVU ® and consider performing laboratory tests in these patients. Use PLENVU ® with caution in patients with renal impairment or those taking concomitant medications that affect renal function.Use PLENVU ® with caution in patients with a history of seizures and those at an increased risk of seizures, including patients taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines, or patients with hyponatremia.Consider obtaining ECGs in patients at an increased risk of serious cardiac arrhythmias. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation.Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. It is encouraged that patients drink additional clear liquids to help avoid cases of fluid and electrolyte abnormalities. Advise patients to hydrate adequately before, during, and after the use of PLENVU ®.PLENVU ® is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic megacolon, and hypersensitivity to any of its ingredients.PLENVU ® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |